Particle Sciences, Inc. (PSI) has acquired exclusive rights to Lyotropics Therapeutics’ LyoCell patent portfolio. The LyoCell technology allows for the solubilization, stabilization, and delivery of a wide range of compounds, both small and large molecule.
 
Under the revenue-share agreement, PSI obtains a full license to the technology except for compounds previously developed by Lyotropics. Particle Sciences will offer the technology to clients looking to increase bioavailability or develop parenteral formulations of difficult-to-solubilize compounds.
 
Robert Lee, PSI’s vice president of Pharmaceutical Development, said, “LyoCells are proprietary lyotropic liquid crystal-based formulations that contain both polar and non-polar nano-domains. These unique structures create ideal conditions for the solubilization and stabilization of many pharmaceuticals and biopharmaceuticals. Made from GRAS ingredients, this technology is already in late-stage clinical development in an intravenous product and has applications in most routes of administration.”
 
Vince Conklin, Lyotropics’ chief executive officer, said, “The LyoCell technology has proven to be highly effective in solving very difficult formulation problems and is the basis for several drugs now in or poised to enter the clinical stage. We are very pleased to have a partner like Particle Sciences, a leader in the formulation and drug delivery space, who is well positioned to further broaden exposure for the LyoCell technology and to employ its enormous utility.”